Recent research ties genetic differences to how well GLP-1 receptor agonists work for weight loss, showing one receptor variant gives a small boost in results while another links to nausea. The study used self-reported outcomes from a large user group and highlights both the promise and the limits of using genetics to personalize these popular treatments. Experts note the findings are intriguing but caution the data are observational and subject to bias.
The rise of GLP-1 drugs has changed weight-loss conversations, but effectiveness varies from person to person. Researchers set out to see whether inherited differences in genes could explain some of that variation with drugs such as semaglutide and tirzepatide. By combining genetic profiles with user-reported outcomes, the study aimed to map which genetic markers correspond with stronger responses or worse side effects.
Analysis of more than 27,000 participants revealed a specific variation in the GLP-1 receptor gene, GLP1R, that acts like a modest booster for treatment effectiveness. People who carried one copy of that variant lost, on average, about 1.6 pounds more than those without it. That signal suggests a future role for genetic information in selecting therapies, even if the advantage is relatively small.
“We believe these reports are a step forward in meeting an unmet need for a more informed and personalized approach to weight management,” said study co-author Noura Abul-Husn, chief medical officer at the 23andMe Research Institute in California, in a press release. The researchers point out that while the genetic effect is measurable, it is modest compared with the population average weight loss of roughly 24 pounds.
Beyond genetics, demographic and treatment choices remain stronger predictors of outcomes. The study found women showed a greater body mass index reduction, about 12.2%, compared with men at 10.0%. Drug type, dosing, age and other clinical factors still dominate how much weight someone ultimately loses.
Investigators also uncovered a different variant tied to higher reports of nausea and vomiting, a common complaint with GLP-1 therapies. Importantly, the presence of that side-effect–linked variant did not reduce the amount of weight lost: patients with GLP1R and GIPR variants lost as much as those without them, but they reported feeling sicker during treatment. That separation between efficacy and tolerability could matter when clinicians balance benefits against quality of life.
POPULAR WEIGHT-LOSS MEDICATIONS LINKED TO HIDDEN SIDE EFFECTS, STUDY FINDS
Dr. Peter Balazs, MD, a hormone and weight-loss specialist not involved in the research, emphasized a drug-specific pattern. “Notably, there appears to be a drug-specific effect: The GIPR variant associated with these side effects is observed with tirzepatide, but not with semaglutide,” he told Fox News Digital. “Additionally, the drug-specific genetic dissociation was unexpected,” he added.
That expert skepticism extends to the study design. The data depend on participants reporting their own weight and symptoms, which opens the door to bias and error. “The data is self-reported and not medically verified, which may affect its reliability firstly,” Balazs told Fox News Digital. “It also does not account for key treatment variables, such as titration, discontinuation or dosing schedules.”
The participant base used in the research may not mirror a broad, real-world population, and the study lacks hard clinical endpoints such as diabetes progression or records of severe adverse events like gastroparesis or pancreatitis. The authors and commentators both warn that many of the associations need confirmation in more controlled, statistically robust studies before clinical practice changes.
A smaller comparison to objective phone-recorded health data suggested people could be over-reporting their progress: where users claimed an 11.8% loss, device data showed about a 5.8% reduction. Because the work is observational rather than a randomized clinical trial, researchers can point to associations between genes and outcomes but cannot prove direct causation.
“I think this article is interesting, raising the possibility of genetic factors, and the use of genetic testing incorporated into further decision-making when picking weight-loss medications,” Balazs said. “However, I would be careful to draw conclusions solely based on this study.”
